The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC).
Iain A. McNeish
No relevant relationships to disclose
Jonathan A. Ledermann
No relevant relationships to disclose
Lee C. Webber
No relevant relationships to disclose
Lindsay E. James
No relevant relationships to disclose
Stanley B. Kaye
Consultant or Advisory Role - AstraZeneca (U)
Honoraria - AstraZeneca
Gordon J. S. Rustin
No relevant relationships to disclose
Geoff Hall
No relevant relationships to disclose
Andrew Clamp
Research Funding - AstraZeneca
Helena Margaret Earl
No relevant relationships to disclose
Susana N. Banerjee
No relevant relationships to disclose
Rebecca Sophie Kristeleit
No relevant relationships to disclose
Fharat Raja
No relevant relationships to disclose
Amanda Feeney
No relevant relationships to disclose
Cheryl Lawrence
No relevant relationships to disclose
Linda Dawson-Athey
No relevant relationships to disclose
Mojca Persic
No relevant relationships to disclose
Iftekhar Khan
No relevant relationships to disclose